Background/Aims: Information on prognostic factors for metastatic colorectal cancer is an important basis for planning the treatment and predicting the outcomes of the patients; however, it has not been well established. The aim of this study was to identify factors that predict results of chemotherapy and to establish a plan for treatment of patients whose tumors are inoperable due to metastatic colorectal cancer. Methods: We conducted a retrospective review of records from 75 patients treated for colorectal cancer in Kosin University Gospel Hospital, from October 2004 to September 2008. Patients with inoperable tumors due to metastasis at the time of diagnosis who were treated with oxaliplatin or irinotecan as the first-line treatment were included in this study. We investigated the factors that might have an effect on overall survival. Results: A total of 75 patients were included in this study. Results of univariate analysis showed that hemoglobin (Hb) ≥10 g/dL at the time of diagnosis, no increase in CEA on the follow-up examination after chemotherapy, chemotherapy plus surgery, and better response to chemotherapy were significant prognostic factors. Results of multivariate analysis showed that Hb ≥10 g/dL at the time of diagnosis (p＜0.001), surgery after chemotherapy (p=0.001), and better response to chemotherapy (p=0.014) were significant prognostic factors. Conclusions: In this study, Hb ≥10 g/dL at the time of diagnosis, surgery after chemotherapy, and better response to chemotherapy were significant prognostic factors for metastatic colorectal cancer. (Korean J Gastroenterol 2014;63:209-215) 
INTRODUCTION
Colorectal cancer, one of the most common malignant tumors, ranks as the third leading cause of cancer-related death worldwide. 1 According to data from the Korean National Cancer Center, the age-standardized incidence rate of colorectal cancer was 27.0 per 100,000 persons in 1999 and 49.8 per 100,000 persons in 2010 in men, and 17.1 per 100,000 persons in 1999 and 26.4 per 100,000 persons in 2010 in women. 2 The overall five-year survival rate of colorectal cancer was 72.6% (74.5% for men and 69.9% for women) in 2006-2010. 2 However, this rate was lower in cases of metastatic disease. A radical cure for colorectal cancer is complete surgical excision; however, in the case of meta-static colorectal cancer, chemotherapy is the treatment of choice.
As the occurrence of colorectal cancer in Korea increases, interest in survival rates after treatment is also increasing.
Some studies have reported several prognostic factors. [3] [4] [5] [6] [7] Some factors appear to have overt effects on cancer prognosis, such as progression of the tumor, depth of invasion, metastasis to other organs, distant metastasis, and lymph node metastasis. Clinical variables, such as age, gender, presence of intestinal obstruction or perforation, location and form of major lesion, and presence of symptoms, bleeding, or transfusion, may also affect prognosis. In addition, pathological prognostic factors have been reported, including DNA ploidy, expression of oncogenes, and tumor associated antigens. However, there are few data on the factors affecting prognosis after initial treatment with chemotherapy for inoperable patients. The aim of this study is to identify factors predicting the results of chemotherapy and to establish a plan for treatment of patients whose tumors are inoperable due to metastatic colorectal cancer.
MATERIALS AND METHODS

Patients
Records from 770 patients treated for colorectal cancer in 
Statistical analysis
Kaplan-Meier analysis was used for evaluation of overall survival, log rank test was used for comparison of differences in prognostic factors, and multivariate analysis by Cox regression proportional hazard model was used for estimation of the prognostic factors affecting overall survival. Statistical analysis was performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA), and a p-value ＜5% was considered significant. (Tables 2, 3 ).
In univariate analysis, age, gender, BMI, and ECOG performance status were not significant prognostic factors af- Fig. 3 . Overall survival according to whether or not follow-up CEA level was elevated. Results of analysis including number of metastases and histological tumor grades showed no statistically significant differences in overall survival. At the time of diagnosis and during the follow-up period, weight loss (≥10%) had no significant effect on overall survival. In addition, decrease in albumin level from the time of diagnosis to the follow-up period did not result in any differences in overall survival. In patients whose hemoglobin level decreased below 10 g/dL at the time of diagnosis (13 patients, 17.3%), median overall survival was significantly decreased compared to patients with hemoglobin ＞10g/dL at the time of diagnosis (4.5 months vs.
months)
. This difference was statistically significant (p ＜0.0001) (Fig. 2) . Increased serum CEA level at the time of diagnosis had no significant effect on overall survival; however, a significant difference in median overall survival was observed in patients whose CEA decreased after chemotherapy (16.87 months vs. 8.87 months, p=0.03) (Fig. 3) .
Patients who had complete remission, partial remission, or SD after chemotherapy had longer overall survival duration than patients who had progression of disease after chemotherapy (15.87 months vs. 5.58 months). This difference was also statistically significant (p=0.02) (Fig. 4) .
In multivariate analysis, significant prognostic factors for metastatic colorectal cancer were hemoglobin ≥10 g/dL at 7 found that sex is a modest independent prognostic marker for patients with early-stage colon cancer, particularly in older patients. In this study, there was no significant difference in prognosis based on age or gender. Ishihara et al. 11 reported that proximal tumor location and female gender were independent predictors of fair prognosis in poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the colon. Meyerhardt et al. 12 reported that obesity is a risk factor for progression of colorectal cancer; however, in this study, neither BMI nor weight change showed a significant association with an increased risk of cancer recurrence or death. In one study, obstruction and perforation are considered major risk factors that decrease survival rates. 13 In general, prognosis of polypoid or protruding cancer is better than that for flat or ulcerative cancer, as it is usually found at an earlier stage and has a lower frequency of lymphatic metastasis or penetration into the wall of the intestine. 14 Patients with symptoms had a better five-year survival rate than patients with no symptoms (71% vs. 49%), because the cancer was found at an earlier stage through a screening inspection. 15 Better five-year survival rate was reported for patients with persistent symptoms over six months. 16 This appears to be related to the tumor growth rate. According to the results of stage-controlled multivariate analysis, the duration of presenting symptoms does not have an effect on patient survival. 17 Rectal bleeding was considered to be a prognostic of better outcomes due to early diagnosis and treatment; however, according to the results of multivariate analysis, rectal bleeding also did not show any association with prognosis. 17 History of transfusion is known to be associated with an increase in cancer recurrence rate and decrease in survival rate. 18 In this study, patients with hemoglobin level ≥10 g/dL (not requiring transfusion) at the time of diagnosis had a remarkably increased median overall survival compared to those with hemoglobin ≤10 g/dL (requiring transfusion). This was a statistically significant difference, and, thus, hemoglobin level at the time of diagnosis was considered to be a helpful prognostic factor.
Most colorectal cancers are histologically consistent with adenocarcinoma. The other histologic types are mucinous-type carcinoma, signet ring cell carcinoma, and undifferentiated carcinoma, which are associated with poor prognoses. The degree of differentiation is an independent factor for survival, as the probability of intestinal wall penetration, lymphogenous metastasis, or remote metastasis increases. 19 In addition to these outcomes, other factors affecting prognosis include invasion of lymphatic vessels, blood vessels, and perineural areas, lymphocytic infiltration around the lesion, and reaction pattern of lymph nodes. [20] [21] [22] One study reported an association between aneuploidy and survival rate, and the stage of disease is known to increase as aneuploidy increases. 23 There is, however, controversy regarding an association between S-phase fraction and survival rate. Allelic loss of chromosome 18q is associated with poor prognosis of colorectal cancer, 24 and DNA index is known to provide better information about prognosis than ploidy. 25 In addition, K-ras mutation or over-expression of ras p21 is related to recurrence of cancer. High expression of p53 has been reported as an independent factor related to decreased survival rate. 26 Mutations in the DCC and nm23 genes may also be related to the prognosis.
An increase in CEA is related to an increase in recurrence rate and lower survival rate. This is more remarkable in an advanced stage of disease and more notable in patients with colon cancer than in those with rectal cancer. 27 In this study, patients with no increase in CEA after chemotherapy had better This study has some limitations. First, this study was retrospective; therefore, we could not avoid selection bias when collecting information. Second, the number of patients with metastatic colorectal cancer included in this study is too small to conclude that these factors are reliable prognostic factors and conduct of further studies including a larger number of patients with metastatic colorectal cancer will be needed in order to verify our findings. Third, this study did not include the response after second line chemotherapy.
Therefore, we did not consider the effect of second line chemotherapy on the prognosis.
In summary, the aim of this study is to analyze the prognostic factors affecting patients with metastatic colorectal cancer who were initially treated with chemotherapy. We found some significant prognostic factors. Results of univariate analysis showed that hemoglobin ≥10 g/dL at the time of diagnosis, no increase in CEA on the follow-up examination after chemotherapy, surgery after chemotherapy, and better response to chemotherapy were significant prognostic factors. According to the results of multivariate analysis, the significant prognostic factors were hemoglobin ≥10 g/dL at the time of diagnosis, surgery after chemotherapy, and better response to chemotherapy.
Conduct of further studies will be needed in order to clarify the prognostic factors affecting metastatic colorectal patients who are initially treated with chemotherapy.
